Which medication class is typically initiated ASAP before discharge after a COPD exacerbation?

The initiation of long-acting bronchodilators is critical in the management of COPD, especially following an exacerbation. This medication class includes long-acting beta-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), both of which play a significant role in improving lung function and reducing symptoms. Following a COPD exacerbation, patients often require stabilization in their lung function, and the use of long-acting bronchodilators helps to achieve this by providing sustained bronchodilation, which improves airflow and reduces respiratory distress.

Administering these medications before discharge ensures that patients have immediate access to the benefits of long-term control medications, promoting adherence to their treatment plan and potentially reducing the risk of future exacerbations. Long-acting bronchodilators are designed for ongoing treatment and are not just intended for acute management; thus, their timely initiation post-exacerbation is essential for long-term management.

Other medication classes may serve important roles in managing COPD exacerbations, but they do not have the same critical importance for immediate initiation upon discharge. For example, antibiotics are typically reserved for specific cases where a bacterial infection is suspected or confirmed, and oral steroids, while beneficial in managing inflammation during an exacerbation, are